Indian authorities have given their first approval for the oral antiviral favipiravir for treatment of COVID-19 to Glenmark Pharmaceuticals.
List view / Grid view
Filter the results
Out of specification results from stability studies have led Glenmark Pharmaceuticals to recall batches of their iohexol solution for injection in the UK.
The FDA grants Orphan Drug Designation to treatments for rare diseases in R&D; here are the 10 most recent for oncologic conditions.
Orphan Drug Designation has been given to bispecific antibody candidate, GBR 1342, for the treatment of multiple myeloma.
3 January 2017 | By Niamh Louise Marriott, Digital Editor
Preclinical studies suggest GBR 1302 may have activity against a range of HER2-expressing tumour types, including breast, gastric and other cancers...
Sanofi and Glenmark Pharmaceuticals sign license agreement on Novel Monoclonal Antibody for Crohn’s Disease
17 May 2011 | By Glenmark Pharmaceuticals
Sanofi to develop molecule for Crohn’s Disease & other anti-inflammatory conditions...